Treatment of acute visual loss in giant cell arteritis: Should we prescribe high-dose intravenous steroids or just oral steroids?

Journal of Neuro-Ophthalmology

Volumn 32, Issue 3, 2012, Pages 278-287

  Hayreh, Sohan Singh ^a   Biousse, Valérie ^b  

^a UNIVERSITY OF IOWA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; METHYLPREDNISOLONE; PREDNISONE;

ACUTE DISEASE; AFFERENT PUPILLARY DEFECT; AGED; BLURRED VISION; CASE REPORT; CATARACT EXTRACTION; CAUCASIAN; CHOLECYSTECTOMY; DIABETES MELLITUS; DRUG MEGADOSE; DRUSEN; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GIANT CELL ARTERITIS; HUMAN; HYPERTENSION; HYSTERECTOMY; ISCHEMIC OPTIC NEUROPATHY; NOTE; OPHTHALMOSCOPY; PRIORITY JOURNAL; VISUAL IMPAIRMENT;

AGED; BLINDNESS; DRUG ADMINISTRATION ROUTES; FEMALE; GIANT CELL ARTERITIS; HUMANS; STEROIDS;

EID: 84865756766     PISSN: 10708022     EISSN: 15365166     Source Type: Journal    
DOI: 10.1097/WNO.0b013e3182688218     Document Type: Note

References (43)

1. Kearns TP. Collagen and rheumatic diseases: Ophthalmic aspects. In: Mausolf FA, ed. The Eye and Systemic Disease. St Louis, MO: Mosby, 1975:105-118.
2. Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology. 2003;110:1204-1215.
3. Matzkin DC, Slamovits TL, Sachs R, Burde RM. Visual recovery in two patients after intravenous methylprednisolone treatment of central retinal artery occlusion secondary to giant-cell arteritis. Ophthalmology. 1992;99:68-71.
4. Weinberg DA, Savino PJ, Sergott RC, Bosley TM. Giant cell arteritis. Corticosteroids, temporal artery biopsy, and blindness. Arch Fam Med. 1994;3:623-627.
5. Liu GT, Glaser JS, Schatz NJ, Smith JL. Visual morbidity in giant cell arteritis -clinical characteristics and prognosis for vision. Ophthalmology. 1994;101:1779-1785.
6. Cornblath WT, Eggenberger ER. Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone. Ophthalmology. 1997;104:854-858.
7. Hwang J-M, Girkin CA, Perry JD, et al. Bilateral ocular ischemic syndrome secondary to giant cell arteritis progressing despite corticosteroid treatment. Am J Ophthalmol. 1999;127:102-104.
8. Schmidt D, Vaith P, Hetzel A. Prevention of serious ophthalmic and cerebral complications in temporal arteritis? Clin Exp Rheumatol. 2000;18(suppl 20):S61-63.
9. Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology. 2005;112:1098-1103.
10. Hayreh SS, Zimmerman B. Management of giant cell arteritis: Our 27-year clinical study; new light on old controversies. Ophthalmologica. 2003;217:239-259.
11. Hayreh SS. Anterior ischaemic optic neuropathy II. Fundus on ophthalmoscopy and fluorescein angiography. Br J Ophthalmol. 1974;58:964-980.
12. Rosenfeld SI, Kosmorsky GS, Klingele TG, Burde RM, Cohn FM. Treatment of temporal arteritis with ocular involvement. Am J Med. 1986;80:143-145.
13. Postel EA, Pollock SC. Recovery of vision in a 47-year-old man with fulminant giant cell arteritis. J Clin Neuroophthalmol. 1993;13:262-270.
14. Hayreh SS, Podhajsky PA, Zimmerman MB. Branch retinal artery occlusion: Natural history of visual outcome. Ophthalmology. 2009;116:1188-1194.
15. Hayreh SS, Zimmerman B. Central retinal artery occlusion: Visual outcome. Am J Ophthalmol 2005;140:376-391.
16. Clearkin L, Caballero J. Recovery of visual function in anterior ischemic optic neuropathy due to giant cell arteritis. Am J Med. 1992;92:703-704.
17. Clearkin LG. IV steroids for central retinal artery occlusion in giant-cell arteritis. Ophthalmology. 1992;99:1482-1484.
18. Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis: Report of a large study and review of literature. Acta Ophthalmol Scand. 2002;80:355-367.
19. Hayreh SS, Zimmerman MB. Non-arteritic anterior ischemic optic neuropathy -natural history of visual outcome. Ophthalmology. 2008;115:298-305.
20. Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology. 2011;118:119-133.
21. Gonzales-Gay MA, Blanco R, Rodriguez-Valverde V, Martinez-Taboada M, Delgado-Rodriguez M, Figueroa M, Uriarte E. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: Predictors and response to treatment. Arthritis Rheum. 1998;41:1497-1504.
22. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372:234-245.
23. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med. 2003;139:505-515.
24. Ghosh P, Borg FA, Dasgupta B. Current understanding and management of giant cell arteritis and polymyalgia rheumatic. Expert Rev Clin Immunol. 2010;913-928.
25. Pipitone N, Boiardi L, Salvarini C. Are steroids alone sufficient for the treatment of giant cell arteritis? Best Pract Res Clin Rheumatol. 2005;19:277-292.
26. Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, Fulcher J, Hollywood J, Hutchings A, James P, Kyle V, Nott J, Powes M, Samanta A. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology. 2010;49:1594-1597.
27. Dashgupta B; on behalf of the Giant Cell Arteritis Guideline Development Group. Concise guidance: Diagnosis and management of giant cell arteritis. Clin Med. 2010;10: 381-386.
28. Ezeonyeji AN, Borg FA, Dasgupta B. Delays in recognition and management of giant cell arteritis: Results from a retrospective audit. Clin Rheumatol. 2011;30:259-262.
29. Lundberg I, Hedfors E. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1990;17:1340-1345.
30. Rahman W, Rahman FZ. Major review -giant cell (temporal) arteritis: An overview and update. Surv Ophthalmol. 2005;50:415-428.
31. Chevalet P, Barrier JH, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, Planchon B, El Kouri D, Connan L, Dupond JL, De Wazieres B, Dien G, Duhamel E, Grosbois B, Jego P, La Strat A, Capedeville J, Letellier P, Agron L. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: A one year followup study of 164 patients. J Rheumatol. 2000;27:1484-1491.
32. Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, Younge BR, Weyard CM, Goronzy JJ. Treatment of giant cell arteritis using induction therapy with high-dose corticosteroids: A double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54:3310-3318.
33. Chan CC, Paine M, O'Day J. Steroid management in giant cell arteritis. Br J Ophthalmol. 2001;85:1061-1064.
34. Aiello PD, Trautman JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant cell arteritis. Ophthalmology. 1993;100:550-555.
35. Kupersmith MJ, Langer R, Mitnick H, Spiera R, Spiera H, Richmond M, Paget S. Visual performance in giant cell arteritis (temporal arteritis) after 1 year of therapy. Br J Ophthalmol. 1999;83:796-801.
36. Foroozan R, Deramo VA, Buono LM, Jayamanne DG, Sergott RC, Danesh-Meyer H, Savino PJ. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology. 2003;110:539-542.
37. Loddenkemper T, Sharma P, Katzan I, Plant GT. Risk factors for early visual deterioration in temporal arteritis. J Neurol Neurosurg Psychiatry. 2007;78:1255-1259.
38. Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum. 2003;32:370-377.
39. Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44:61-98.
40. Franchin G, Diamond B. Pulse Steroids: How much is enough? Autoimmunity Rev. 2006;5:111-113.
41. Hayreh SS. Steroid therapy for visual loss in patients with giant-cell arteritis. Lancet. 2000;355:1572-1573; 356:434.
42. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347:261-271.
43. Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: Ocular manifestations. Am J Ophthalmol. 1998;125:521-526.